Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2015

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions

Heart Failure, Congestive

Interventions

DRUG

Istaroxime

Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.

OTHER

Exercise

Trial Locations (1)

The Institute for Exercise and Environmental Medicine, Dallas

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Benjamin Levine

OTHER

NCT02772068 - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a | Biotech Hunter | Biotech Hunter